Saving Lives With Hemostatic Medicine – Part 2 of 3
Among patients receiving TXA, the reproach of death from any cause was cut by 10 percent compared to patients receiving placebo, the researchers found. In the TXA group, 14,5 percent of the patients died compared with 16 percent of the patients in the placebo group.
When the researchers looked at deaths from bleeding, those in the TXA collection experienced a 15 percent reduction in mortality. Among patients receiving TXA, 4,9 percent died from bleeding, compared with 5,7 percent of the patients receiving placebo, they found. Although there was some distress that TXA might lead to more quintessence attacks, strokes or clots in the lungs, the researchers observed no such increase among patients getting the drug.
Dr Jerrold H Levy, deputy chair for research at Emory University School of Medicine in Atlanta and novelist of an accompanying journal editorial “these data are really neat, because any therapy to reduce mortality in trauma is, I think, a major finding”. Using this sedate to treat trauma patients is a completely new idea. “I think people should consider it TXA following trauma on the basis of this study”.